Bryon D. Johnson

5.0k total citations · 1 hit paper
140 papers, 3.9k citations indexed

About

Bryon D. Johnson is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Bryon D. Johnson has authored 140 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Immunology, 70 papers in Oncology and 32 papers in Hematology. Recurrent topics in Bryon D. Johnson's work include CAR-T cell therapy research (53 papers), Immune Cell Function and Interaction (33 papers) and Immunotherapy and Immune Responses (32 papers). Bryon D. Johnson is often cited by papers focused on CAR-T cell therapy research (53 papers), Immune Cell Function and Interaction (33 papers) and Immunotherapy and Immune Responses (32 papers). Bryon D. Johnson collaborates with scholars based in United States, France and Germany. Bryon D. Johnson's co-authors include Weiqing Jing, Rimas J. Orentas, Robert L. Truitt, Jill A. Gershan, William R. Drobyski, Parameswaran Hari, Nirav N. Shah, Michael B. Dwinell, Katie Palen and Laura McOlash and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Bryon D. Johnson

132 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

2020 318 citations Nirav N. Shah, Bryon D. Johnson et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryon D. Johnson United States	33	1.9k	1.8k	956	939	471	140	3.9k
Evelyn Ullrich Germany	33	1.9k 1.0×	2.6k 1.4×	440 0.5×	940 1.0×	171 0.4×	116	3.6k
Lucia Gabriele Italy	35	1.5k 0.8×	2.5k 1.4×	278 0.3×	1.1k 1.2×	426 0.9×	74	4.3k
David Spaner Canada	35	1.9k 1.0×	1.8k 1.0×	554 0.6×	1.4k 1.5×	276 0.6×	123	4.7k
Shivani Srivastava United States	25	1.9k 1.0×	1.8k 1.0×	292 0.3×	740 0.8×	484 1.0×	58	3.3k
Sebastian Kobold Germany	36	3.3k 1.7×	2.7k 1.5×	297 0.3×	1.7k 1.8×	775 1.6×	141	5.5k
Stéphane Depil France	29	2.4k 1.3×	1.6k 0.9×	220 0.2×	1.7k 1.8×	549 1.2×	70	4.0k
Carmela De Santo United Kingdom	25	1.3k 0.7×	2.6k 1.5×	307 0.3×	752 0.8×	160 0.3×	40	3.6k
Angelica Loskog Sweden	37	2.8k 1.5×	2.2k 1.3×	200 0.2×	1.3k 1.4×	420 0.9×	103	4.6k
Segundo González Spain	44	1.6k 0.8×	3.5k 2.0×	648 0.7×	845 0.9×	121 0.3×	109	5.2k
Viktor Umansky Germany	31	2.9k 1.5×	4.4k 2.5×	269 0.3×	1.7k 1.8×	322 0.7×	60	6.3k

Countries citing papers authored by Bryon D. Johnson

Since Specialization

Citations

This map shows the geographic impact of Bryon D. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryon D. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryon D. Johnson more than expected).

Fields of papers citing papers by Bryon D. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryon D. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryon D. Johnson. The network helps show where Bryon D. Johnson may publish in the future.

Co-authorship network of co-authors of Bryon D. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Bryon D. Johnson. A scholar is included among the top collaborators of Bryon D. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryon D. Johnson. Bryon D. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Nirav N., Bryon D. Johnson, Anikó Szabó, et al.. (2025). Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. 43(20). 2285–2295. 2 indexed citations

Bates, Paul D., et al.. (2025). TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant. Journal for ImmunoTherapy of Cancer. 13(12). e010239–e010239.

Furqan, Fateeha, Katie Palen, Bryon D. Johnson, et al.. (2024). Combination of Pirtobrutinib and Lentiviral Transduced Bispecific Anti-CD20/CD19 (LV20 .19) CAR T-Cell Therapy to Improve Outcomes in Patients With Relapsed/Refractory Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S220–S220.

Zhang, Qi, Xu Chen, Katie Palen, et al.. (2023). Cancer chemoprevention with PV-1, a novel Prunella vulgaris-containing herbal mixture that remodels the tumor immune microenvironment in mice. Frontiers in Immunology. 14. 1196434–1196434. 7 indexed citations

Shah, Nirav N., Fateeha Furqan, Anikó Szabó, et al.. (2023). Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma. Transplantation and Cellular Therapy. 29(2). S33–S34. 1 indexed citations

Knight, Jennifer M., Anikó Szabó, Sharon Yim, et al.. (2022). Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. SHILAP Revista de lepidopterología. 2(1). 49–49. 9 indexed citations

Shah, Nirav N., Joanna Zurko, Timothy S. Fenske, et al.. (2021). Clinical and Manufacturing Outcomes of LV20.19 CAR T-Cells Expanded in IL-2 Versus IL-7 and IL-15. Transplantation and Cellular Therapy. 27(3). S194–S195. 1 indexed citations

Mohammed, Altaf, Roderick H. Dashwood, Sally E. Dickinson, et al.. (2021). Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. Journal of Cancer Prevention. 26(4). 309–317. 1 indexed citations

Zurko, Joanna, Huiqing Xu, Dina Schneider, et al.. (2021). Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose. Blood. 138(Supplement 1). 3883–3883. 2 indexed citations

10.

Shah, Nirav N., Bryon D. Johnson, Dina Schneider, et al.. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine. 26(10). 1569–1575. 318 indexed citations breakdown →

11.

Badar, Talha, Bryon D. Johnson, & Mehdi Hamadani. (2020). Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation. 56(3). 683–685. 13 indexed citations

12.

Pan, Jing, Qi Zhang, Katie Palen, et al.. (2019). Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. EBioMedicine. 49. 72–81. 49 indexed citations

13.

Badar, Talha, Binod Dhakal, Anikó Szabó, et al.. (2019). An updated single center experience with plerixafor and granulocyte colony‐stimulating factor for stem cell mobilization in light chain amyloidosis. Journal of Clinical Apheresis. 34(6). 686–691. 1 indexed citations

14.

Jing, Weiqing, Donna McAllister, Katie Palen, et al.. (2019). STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. Journal for ImmunoTherapy of Cancer. 7(1). 115–115. 153 indexed citations

15.

Jing, Weiqing, Jill A. Gershan, Sandra Holzhauer, et al.. (2017). T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. Cancer Research. 77(20). 5676–5686. 17 indexed citations

16.

Thakar, Monica S., Parameswaran Hari, John A. Charlson, et al.. (2017). Haploidentical Hematopoietic Cell Transplantation Followed By Donor Natural Killer Cell Infusion and Sirolimus Maintenance Can Successfully Treat Patients with High-Risk Ewing Sarcoma. Blood. 130. 4525. 1 indexed citations

17.

Cheng, Gang, Jacek Zielonka, Olivier Ouari, et al.. (2016). Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. Cancer Research. 76(13). 3904–3915. 168 indexed citations

18.

Kohler, M. Eric, William Hallett, Qingrong Chen, et al.. (2010). Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. Cellular Immunology. 265(1). 65–73. 4 indexed citations

19.

Zhou, Qiang, Xiaocai Yan, Jill A. Gershan, Rimas J. Orentas, & Bryon D. Johnson. (2008). Expression of Macrophage Migration Inhibitory Factor by Neuroblastoma Leads to the Inhibition of Antitumor T Cell Reactivity In Vivo. The Journal of Immunology. 181(3). 1877–1886. 31 indexed citations

20.

Chen, Xiaohong, Sanja Vodanovic‐Jankovic, Bryon D. Johnson, et al.. (2007). Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 110(10). 3804–3813. 182 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact